Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTX-958 (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms Harmony-CD
  • Sponsors Ventyx Biosciences

Most Recent Events

  • 08 May 2025 According to a Ventyx Biosciences media release, the company announced the presentation of Phase 2 data for VTX958 in Crohn's disease at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO, February 2025, Journal of Crohn's and Colitis, doi.org/10.1093/ecco-jcc/jjae190.1175).
  • 18 Feb 2025 According to a Ventyx Biosciences media release, Based on results from this trial, and recognizing the unmet need and opportunity for a safe and effective oral TYK2 inhibitor as early-line therapy in Crohns disease, company is continuing the analysis of the Phase 2 data including data from the 52-week treat-through long-term extension phase.
  • 18 Feb 2025 According to a Ventyx Biosciences media release, the company announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohns disease will be presented during the 20th Congress of the European Crohns and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top